Analyst ratings published on MarketBeat for Monopar Therapeutics, which trades on the Nasdaq stock exchange.
2 reports, 1 independent
Updated Aug 27
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Analyst ratings published on MarketBeat for Monopar Therapeutics, which trades on the Nasdaq stock exchange.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Monopar Therapeutics received research reports and ratings from Cantor Fitzgerald and Morgan Stanley.1 source
Analyst ratings published on MarketBeat for Monopar Therapeutics.1 source
Keep exploring
The entities involved
-
MarketBeat
American personal finance blog
Nothing else this week.
-
Monopar Therapeutics
biopharmaceutical company
Nothing else this week.
-
Nasdaq
American fully electronic stock exchange
Related events
- MarketBeat is reporting on consensus ratings for Aehr Test Systems, a company whose stock trades on the Nasdaq exchange.
- MarketBeat provided analyst ratings for MarketAxess, a company listed on the Nasdaq exchange.
- MarketBeat reported an average stock rating for Superior Group of Companies.
- MarketBeat reported analyst ratings for Sarepta Therapeutics and Emergent BioSolutions, both of which are listed on Nasdaq.
- MarketBeat provided stock average ratings while Leerink Partners upgraded and Barclays raised its price objective for Summit Therapeutics.